A cure for acid flashbacks

Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD

Ehave Inc. (EHVVF) and University of Melbourne are launching a series of studies to better understand a condition called hallucinogen-persisting perception disorder (HPPD). Basically, HPPD is when someone continues to experience visual hallucinations after a trip.

Researchers will conduct genetic analysis and visual processing tests to see if individuals can be genetically predisposed to HPPD. 

Ehave’s goal is to find a cure for the disorder and become an “industry leader in preventing negative side effects during treatment for mental health issues.”

PDF of article

Curing a side effect of psychedelics

Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave

Psychedelic drugs (typically LSD but sometimes psilocybin or other substances) can occasionally cause lasting visual disturbances such as seeing bright spots of light, distorted sizes and colours,  or halos around objects  – a disorder called Hallucinogen Persisting Perception Disorder (HPPD).

Scientists don’t know exactly why this occurs, but Ehave Inc. (EHVVF) is on a mission to get to the bottom of it. Ehave will be conducting a series of studies over 12 months to determine the cause of HPPD and hopefully find a way to prevent or cure it too. The company strongly believes that there’s a genetic predisposition to the disorder, so the study will involve genetic analysis of 2000 patients and may lead to a genetic test for HPPD susceptibility.

“Let me be clear, psychedelics are extremely safe, especially when used under medical supervision. Understanding HPPD, however, will lead to a better understanding of these molecules as a whole,” said Ehave’s CEO.

PDF of article